Breast Cancer


What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer? (07-25-2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion of an initial 5 years of treatment. The optimal... Continue Reading

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer (07-23-2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor... Continue Reading

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients (07-9-2018)

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence... Continue Reading

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation (06-21-2018)

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy... Continue Reading

Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer (04-19-2018)

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant differences in effectiveness or safety, For... Continue Reading

FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer (03-26-2018)

CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant treatment of patients with HER2-positive early... Continue Reading

At-home Genetic Testing may be Convenient, but it isn’t Complete (03-20-2018)

March 14, 2018 https://www.statnews.com/2018/03/14/genetic-testing-23andme-brca/   Home delivery for everything from fresh produce to custom-selected clothing has become a way of life for many Americans. While most home-delivery conveniences are generally... Continue Reading

FDA Approval for Verzenio™ as Initial Treatment for Advanced Breast Cancer (03-12-2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive... Continue Reading

Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast Cancer (02-21-2018)

A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer (TNBC), according to new research published by a multi-institutional... Continue Reading

Five Common Sign & Symptoms of Breast Cancer (02-12-2018)

CancerConnect News: Breast cancer is a cancer that originates in the area of the breast, where cells replicate too quickly, causing a tumor. Breast cancer is most common in women, but I can also occur in men. Breast cancer is caused by an abnormality... Continue Reading

Next Page »